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SUMMARY
Skin cancer is rare in people of African origin while vitiligo occurs worldwide. The 
occurrence of primary malignant melanoma and vitiligo together is very rare. We present 
a rare case of primary malignant amelanotic melanoma arising from a depigmented 
patch of a patient with vitiligo. It was completely excised and followed for one year. 
No recurrence or metastases was noted during the follow up period.
INTRODUCTION
Malignant melanoma is a rare tumour in people of 
African descent including those affected by albinism 
(1). The incidence of malignant melanoma in Africans 
is estimated to ranging from 0.5 to 1.5 per 100,000 
people (2). Acrolentiginous melanoma is the most 
common type of melanoma in this population. Ultra 
violet radiation does not appear to be a significant risk 
factor for melanoma in blacks who tend to develop 
melanoma on acral, non-sun-exposed areas (2).
CASE REPORT
A 32 year old female presented with a four year 
history of depigmented patches on the face, trunk 
and extremities. The depigmented patches were 
irregular, well demarcated and non-pruritic. Both 
upper and lower limbs were affected but sparing 
the hands and the feet. After three years of having 
depigmented patches, a small nodule appeared in 
the centre of a depigmented patch on the left leg. 
The nodule rapidly increased in size and became 
ulcerated. Within six months the tumour had grown 
to a size of four centimeters in diameter (Figure 1). 
Thorough examination of the left limb did not reveal 
any other growths. The inguinal lymph nodes were 
not enlarged. She had no personal or family history 
of melanoma. 
Figure 1
Lateral and aerial view of a tumour arising from the centre of a vitiligo patch. The Brown coloration is due to 
povidone iodine
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An excision was done with a one centimetre safety 
margin and deeper to sub-cutaneous tissue. The 
margins were examined histologically to confirm 
complete excision. Histologically, the tumour 
composed of nested atypical melanocyte (Figure 2). 
The tumour cells expressed S-100, Melan-A (Figure 
3) and HMB-45. There were many mitotic figures and 
proliferation activity was high when assessed with 
MIB-1. At one year follow up there was complete 
healing without recurrence and no changes in the 
inguinal nodes. 
Figure 2
Hematoxylin and Eosin staininig showing nested 
atypical melanocytes (X10)
Figure 3
Tumour cells stained positive with Melan-A (X10)
DISCUSSION 
The prevalence of vitiligo in the general population is 
estimated at 1% (3) while the prevalence of vitiligo in 
patients with malignant melanoma has been reported 
to range from 3-6% (4,5). Different depigmentary 
changes associated with melanoma have been 
reported. These pigmentary changes include halo 
nevus, achromic patches on melanoma scars, 
depigmentation of injection site after immunotherapy 
and depigmentation associated with regressing 
malignant melanoma. The association of vitiligo with 
regressing melanoma has been widely reported in 
literature, however primary melanoma presenting 
initially with vitiligo is very rare. Lugo-Somolinus 
et al (6) reported two cases of vitiligo-like primary 
melanoma. We are reporting a similar case of primary 
melanoma arising in vitiliginous lesion.
 The pathologic mechanism of vitiligo is not 
clearly known. Complex factors involving cellular 
and humoral immunity, toxic metabolites and genetic 
factors partly contribute to its pathogenesis. Ciu et al 
(7) demonstrated that antibodies to melanocytes were 
present in both vitiligo and melanoma patients and 
these antibodies were directed to similar melanocyte 
antigens. The implicated antigens are tyrosinase, 
melan A, gp100 and TRP-28. This association 
explains the simultaneous appearance of vitiligo 
and regressing melanoma, however it contradicts 
the occurrence of melanoma in vitiligo lesions. 
 Tobin et al (9) observed that melanocytes are never 
completely cleared from vitiligo lesions and that this 
melanocyte can recover their functionality. Similarly, 
Gottschalk et al (10) reported melanocyte survival 
in three cases of vitiligo which had been inactive for 
two to five years. Melanoma may develop from these 
melanocytes that have escaped immune destruction. 
The mechanisms of immune escape are not clearly 
known but Le Poole et al (11) hypothesised that the 
tumour escape may be due to early activation of 
T-cells secreting IFN-α which contribute to tumour 
escape and development of vitiligo. Vitiligo-like 
lesions are generally regarded as a good prognostic 
factor in melanoma patients (12,13). The survival 
rate of these patients has been shown to be better 
than would have been expected for a patient with a 
similar melanoma stage. This may be attributed to 
destruction of melanocyte by an enhanced immune 
response.
In conclusion, this is a rare presentation of a rapidly 
growing primary malignant amelanotic melanoma 
arising from vitiligo lesions without evidence of 
tumour elsewhere. The one year follow up period 
might be short to assess the recurrence. 
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